## Supplementary Table

List of clinical practice guidelines for the management of ovarian cancer

<table>
<thead>
<tr>
<th>Country</th>
<th>Organization</th>
<th>Included guideline(s)</th>
<th>Years published/revised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Norway</td>
<td>Norwegian Directorate of Health (NDH)</td>
<td>Gynecological cancer - national action programme with guidelines for diagnosis, treatment and follow-up¹</td>
<td>2016</td>
</tr>
<tr>
<td>Australia</td>
<td>Cancer Australia (CA)</td>
<td>Recommendations for the management of women at high risk of ovarian cancer²</td>
<td>2004, 2011</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Optimal Care Pathway for Women with Ovarian Cancer⁴</td>
<td></td>
</tr>
<tr>
<td></td>
<td>British Columbia Cancer</td>
<td>Ovary – Epithelial Carcinoma⁷</td>
<td>2018</td>
</tr>
<tr>
<td></td>
<td>Cancer Care Ontario (CCO)</td>
<td>The Role of Intraperitoneal Chemotherapy in the First-line Treatment of Women with Stage III Epithelial Ovarian Cancer⁸</td>
<td>2006, 2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Management of a suspicious adnexal mass⁹</td>
<td>2011, 2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Organizational Guideline for Gynecologic Oncology Services in Ontario Systemic Therapy for Recurrent Epithelial Ovarian Cancer¹¹</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Serous Epithelial Ovarian Cancer Treatment and Follow-up Pathway Map¹²</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ultra-radical (extensive) surgery for advanced ovarian cancer¹⁴</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer¹⁵</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy¹⁶</td>
<td></td>
</tr>
<tr>
<td></td>
<td>British Gynaecological Cancer Society (BGCS)</td>
<td>Epithelial Ovarian / Fallopian Tube / Primary Peritoneal Cancer Guidelines: Recommendations for Practice¹⁷</td>
<td>2019</td>
</tr>
<tr>
<td>Scotland</td>
<td>Scottish Intercollegiate Guidelines Network (SIGN)</td>
<td>Management of epithelial ovarian cancer¹⁸</td>
<td>2003, 2013, 2018</td>
</tr>
<tr>
<td>South Wales</td>
<td>South Wales Cancer Network (SWCN)</td>
<td>South Wales Gynaecology Clinical Guidelines¹⁹</td>
<td>2011</td>
</tr>
<tr>
<td>North Wales</td>
<td>North Wales Cancer Network (NWCN)</td>
<td>North Wales Ovarian Cancer Guidelines²⁰</td>
<td>2015</td>
</tr>
<tr>
<td>Ireland</td>
<td>Northern Ireland Cancer Network (NicAn)</td>
<td>Systematic Anti-Cancer Therapy (SACT) Guidelines for Ovarian Cancer²¹</td>
<td>2017</td>
</tr>
<tr>
<td>New Zealand</td>
<td>New Zealand Ministry of Health (NZMH)</td>
<td>Standards of Service Provision for Gynaecological Cancer Patients in New Zealand – Provisional²²</td>
<td>2013</td>
</tr>
<tr>
<td>Ireland</td>
<td>National Cancer Control Programme (NCCP)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>National Comprehensive Cancer Network (NCCN)</td>
<td>Epithelial Ovarian Cancer²³</td>
<td>2019*</td>
</tr>
<tr>
<td>international guidelines</td>
<td>American Society of Clinical Oncology (ASCO)</td>
<td>Neoadjuvant Chemotherapy for Ovarian Cancer²⁴</td>
<td>2016</td>
</tr>
<tr>
<td></td>
<td>European Society of Medical Oncology (ESMO)</td>
<td>Newly Diagnosed and Relapsed Epithelial Ovarian Carcinoma: ESMO Clinical Practice Guidelines²⁵</td>
<td>2013, 2016</td>
</tr>
<tr>
<td></td>
<td>European Society of Gynaecological Oncology (ESGO)</td>
<td>Ovarian Cancer Surgery Guidelines²⁶</td>
<td>2017</td>
</tr>
</tbody>
</table>

*Updated on a continuous basis, at least annually
Additional references:

1 Norwegian Directorate for Health (NDH). Gynecological cancer - national action programme with guidelines for diagnosis, treatment and follow-up. NDH National Professional Guidelines 2016. Available at: https://www.helsedirektoratet.no/retningslinjer/gynekologisk-kreft-handlingsprogram


10 Members of the Gynecology Cancer Disease Site Group. First-line Chemotherapy for Postoperative Patients with Stage II, III or IV Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. Cancer Care Ontario (CCO) 2013.


12 Cancer Care Ontario. Serous Epithelial Ovarian Cancer Treatment and Follow-up Pathway Map (version 2018.06). Available at: https://www.cancercareontario.ca/sites/ccocancercare/files/assets/CCOvarySerousTreatmentPathway.pdf


16 NICE. Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy [TA598]. Published 28th August 2019. Available at: https://www.nice.org.uk/guidance/ta598


